Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are becoming increasingly popular in Ethiopia, with a growing number of people seeking relief from respiratory illnesses.
Customer preferences: As with other countries, the demand for bronchodilator drugs in Ethiopia is driven by the prevalence of respiratory illnesses such as asthma and chronic obstructive pulmonary disease (COPD). In addition, the country’s high levels of air pollution contribute to the development of these conditions, leading to a higher demand for bronchodilator drugs.
Trends in the market: The market for bronchodilator drugs in Ethiopia is expected to grow significantly in the coming years, driven by a number of factors. Firstly, the country’s population is growing rapidly, leading to an increase in the number of people suffering from respiratory illnesses. Secondly, there is a growing awareness of the benefits of bronchodilator drugs, leading to more people seeking treatment. Finally, the government is investing in healthcare infrastructure, making it easier for people to access these drugs.
Local special circumstances: One of the unique challenges facing the bronchodilator drugs market in Ethiopia is the lack of access to healthcare in rural areas. While the government is investing in healthcare infrastructure, many people in rural areas still struggle to access basic healthcare services, let alone more specialized treatments such as bronchodilator drugs. This presents a significant challenge for companies looking to expand their market share in Ethiopia.
Underlying macroeconomic factors: Ethiopia is one of the fastest-growing economies in Africa, with a growing middle class and a rapidly expanding consumer market. This presents a significant opportunity for companies operating in the bronchodilator drugs market, as more people are able to afford these treatments. However, the country also faces a number of challenges, including high levels of poverty and political instability, which could impact the growth of the market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
